retatrutide phase 2 nejm 2023 obesity trial results Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks Phase 2 Trial of Retatrutide

BMJ (2018) 360:k872

In contrast, Ucn2 and Ucn3 bind with much higher affinity than CRF to CRF2 and are therefore, are likely to be the endogenous ligands of this receptor

Patients are also educated on recognizing warning signs and when to escalate care

While the effects on beta-cell mass, apoptosis and proliferation have also been demonstrated with liraglutide in young rodents (161, 162), they have not been shown to translate into a clinically significant effect in terms of the permanent prevention of diabetes progression, most likely because the effects on beta-cell mass are specific to younger animals and human beta-cells have a much lower, if any, capacity for regeneration (163, 164)